Skip to main content

Biologic/Novel Rx

FDA Approves Taltz for Non-Radiographic Axial Spondyloarthritis

Jun 01, 2020

Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Ixekizumab (an IL-17A inhibitor) would join certolizumab (TNF inhibitor) as the only 2 drugs approved by the FDA for nr-

Read Article

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers.

Dr. John Cush RheumNow ( View Tweet)

May 28, 2020

TNR Grand Rounds - Cytokine Storm Syndromes

May 27, 2020

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The

Read Article

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

May 25, 2020

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article
Case report in Annals Internal Med shows efficacy of tocilizumab in Cytokine Storm Syndrome; 51-yo renal transplant COVID+ pt developed multiorgan failure, cytopenias, CRP 262 mg/L, ferritin 52005 - failed MMF, DEX, tacrolimus- turned around w/ TCZ 8mg/kg https://t

Dr. John Cush RheumNow ( View Tweet)

May 22, 2020

No Certain Link between Biologics and Melanoma Risk

May 21, 2020

A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.  



There have been sporadic uncontrolled observational reports suggesting a link between

Read Article
A patient service Video - How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/hWW0h8wCZn or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5
Dr. John Cush RheumNow ( View Tweet)
May 21, 2020
JAK inhibr safety review - Meta-analysis shows a significant 57% increase in risk of H. zoster with JAKi (RR 1.57; 1.04-2.37). Data from 82 studies, 66,159 pts w/ RA, IBD, Pso, PsA, AS. Rates of SIE=2.81/100PY and HZ=2.67/100 PY.

Dr. John Cush RheumNow ( View Tweet)

May 21, 2020

Anti-TNF and CNS Events: The Link Strengthens

May 20, 2020

Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.

Read Article

TNR - COVID-Rheumatology Registry & COVID in OZ

May 19, 2020

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in

Read Article

Systemic Sclerosis Future Therapies and Outcome Measures

May 19, 2020

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,

Read Article
Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months.

Dr. John Cush RheumNow ( View Tweet)

May 18, 2020

High Dose Anakinra Effective in COVID-19

May 18, 2020

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared

Read Article
Subanalyses of Mobility and Monarch studies show that #RA patients with highest tertiles of IL-6 (and CRP) had more disease activity, more Xray damage and better responses (less Xray change) to Sarilumab (vs Adalimumab or MTX). https://t.co/5mTePETFAQ

Dr. John Cush RheumNow ( View Tweet)

May 12, 2020

Secukinumab Better than Adalimumab - Maybe?

May 11, 2020

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher

Read Article
Anakinra studied in COVID(+) ARDS (nonICU) pts w/ high CRP L or ferritin; 29 high dose Anakinra vs 17 controls. At day 21, more survival with anakinra 90% vs. Controls 56% (p=0·009).

Dr. John Cush RheumNow ( View Tweet)

May 11, 2020
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv

Dr. John Cush RheumNow ( View Tweet)

May 10, 2020
Anakinra works in CPPD. Metanalysis of biologics use finds 74 pts Rx with anakinra for refractory dz (85%) or w/ contraindications (23%). Anakinra resp seen in 81% of acute and 43% of chronic CPPD pts. Few adverse events reported (4.1%) https://t.co/PwJO4ta6i7

Dr. John Cush RheumNow ( View Tweet)

May 08, 2020

RheumNow Podcast – The Beat Goes On (5.8.20)

May 07, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome” https://t.co/FYsr77a68Z Meeting ID: 934 0443 3549

Dr. John Cush RheumNow ( View Tweet)

May 07, 2020
Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3

Dr. John Cush RheumNow ( View Tweet)

May 07, 2020

COVID-19 and Thrombotic Complications

May 07, 2020

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection. Rising high on the list of complications are the hematologic and vascular complications seen in severely affected patients, so much so that many centers are

Read Article
Italian study of 1193 Psoriasis pts, there were 17 biologic (TNF, UST, IL17 IL23) treated COVID cases. When compared to 19 local nonPSO/Nonbiologic pts.

Dr. John Cush RheumNow ( View Tweet)

May 07, 2020
×